Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02023047
Other study ID # RDD 112
Secondary ID
Status Terminated
Phase Phase 1/Phase 2
First received December 11, 2013
Last updated November 15, 2015
Start date March 2014
Est. completion date November 2015

Study information

Verified date January 2015
Source RDD Pharma Ltd
Contact n/a
Is FDA regulated No
Health authority Israel: Ministry of Health
Study type Interventional

Clinical Trial Summary

This is an open label study. The study will consist of 2 treatment group: coated Nifedipine suppository containing 12 mg of Nifedipine applied twice daily (group 1) and coated Nifedipine suppository containing 12 mg of Nifedipine applied once daily (group 2). Approximately 30 subjects will participate into this 8-week study. The primary objective is to examine the dose effect of coated Nifedipine suppository on Anal fissure pain and healing.


Description:

This is an open label study. The study will consist of 2 treatment group: coated Nifedipine suppository containing 12 mg of Nifedipine applied twice daily (group 1) and coated Nifedipine suppository containing 12 mg of Nifedipine applied once daily (group 2). Approximately 30 subjects will participate into this 8-week study. A screening visit will be used to determine subject suitability for inclusion in the trial. Within one week of the screening visit, subjects who meet all inclusion criteria and none of the exclusion criteria will receive Coated Nifedipine 12 mg Suppository X2 a day (BID) (24 mg/day total) OR Coated Nifedipine 12 mg Suppository X1 a day (OD) (12 mg/day total) for a period of 8 weeks. During this period, 4 study visits (at 0, 2, 5, and 8 weeks) will take place. Study medication will be administered BID (in the morning and in the evening) or OD (only in the morning). In addition to receiving study medication, subjects will be maintained on a standard treatment for Anal Fissure: sitz baths, high fiber diet.


Recruitment information / eligibility

Status Terminated
Enrollment 33
Est. completion date November 2015
Est. primary completion date November 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Single anal fissure

- Signed written informed consent;

- Male or female subjects 18 to 65 years of age;

- Has chronic anal fissure defined as history of anal pain at least three days a week for 30 days duration or more

- Visible fibers of the internal sphincter were seen at the base of the fissure or if a sentinel pile was present.

- VAS of > 35 mm in screening visit

- If female, is non-lactating, has a negative urine pregnancy test result, and does not plan on becoming pregnant during the study, or not of childbearing potential (hysterectomy or tubal ligation at least 6 months prior to entry to the study or post-menopausal for 1 year); if of childbearing potential (including peri-menopausal women who have had a menstrual period within one year) must practice or be willing to continue to practice appropriate birth control (such as implants, injectables, oral contraceptives, some intrauterine contraceptive devices, sexual abstinence, tubal ligation, or a vasectomized partner) during the entire study duration.

Exclusion Criteria:

- Known allergy to Nifedipine, polyethylene-glycol, propylene Glycol or silicone.

- Fissure resulting from inflammatory bowel disease, venereal disease, perianal psoriasis, immunodeficiency syndrome.

- Anal abscess

- Fixed anal stenosis

- Active or past history of cardiovascular or cerebrovascular disease including unstable angina, myocardial infarction, transient ischemic attacks/stroke, clinically significant arrhythmia, moderate to severe congestive heart failure, or cardiac valve abnormalities;

- Type 1 diabetes mellitus;

- Insulin treated type 2 diabetes mellitus;

- History of Renal insufficiency.

- History of Liver insufficiency.

- Malignant disease within 5 years of screening;

- Has uncontrolled hypertension (sitting blood pressure <160/95 mmHg at screening)

- History of chronic gastrointestinal disease.

- History of rectal surgery.

- History of gastrointestinal surgery.

- History of HIV, hepatitis B, hepatitis C.

- In need of chronic use of medication, with the exception of birth control medications.

- Currently uses medication for acute illness (other than medications for use of treatment/pain relief of anal fissure).

- Has used, in the last two weeks, drugs that may affect blood coagulation, such as Aspirin at a dose higher than 500 mg/day , Warfarin, Sintrom, Enoxaparin, Nadroparin, Heparin, Clopidogrel, Ticlopidine.

- Is using drug that may affect rectal tone:

- Calcium Channel Blocker such as:

- Nifedipine (Osmo-Adlat, Pressolat, Nifedipine -Teva, Nifedilong)

- Amlodipine (Amlow, Norvasc, Amlodipine-Teva)

- Lercadipine (Vasodip)

- Verapamil (Ikacor, Ikapress, Verapress)

- Felodipine (Penedil)

- Diltiazem (Adizem, Dilatam)

- Nitrate donors such as:

- Glyceryl Trinitrate (Deponit)

- Isosorbid dinitrate (Isoket, Isolong)

- Isosrbid mononitrate (Monocord, Monolong, Mononit)

- Nitroglycerine (Nitrocine, Nitroderm, Nitrolingual)

- Has upon physical examination a rectal deformation or signs of rectal disease such as bleeding hemorrhoids, fistula. infection or space occupying lesion.

- Is an immediate family member of personnel directly affiliated with the study at the investigative site, or is personally directly affiliated with the study at the investigative site; or

- Is employed by RDD Pharma Ltd.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Nifedipine 12 mg coated suppositories


Locations

Country Name City State
Israel Macabi outpatient clinic Beer Sheba Negev
Israel Macabi outpatient clinic Rehovot
Israel Macabi HMO outpatient clinic Tel Aviv
Israel Asaf Harofe Hospital Zrifin

Sponsors (1)

Lead Sponsor Collaborator
RDD Pharma Ltd

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary To examine the effect of coated Nifedipine suppository on Anal fissure pain as measured by Visual Analog Score 8 weeks after study initiation No
Secondary To investigate the Safety and tolerability of coated Nifedipine suppositories in Anal Fissure patients . safety will be assessed by the number of participants with adverse events. Tolerability will be assessed by the number of participants that discontinue treatment. 8 weeks Yes
See also
  Status Clinical Trial Phase
Completed NCT06216223 - Laser Versus Surgery in Anal Diseases in Inflammatory Bowel Patients N/A
Not yet recruiting NCT05405634 - Microbiota in Chronic Anal Fissure and Its Association With Prognosis
Completed NCT05736926 - Anal Fissure Among Survivors of COVID-19 Virus Infection.
Enrolling by invitation NCT00980369 - The Importance of Lateral Internal Sphincterotomy Incision: Parallel or Vertical N/A
Completed NCT05616455 - Efficacy and Safety of Propionibacterium Extract Gel Versus 0.4% Glyceryl Trinitrate Ointment in the Treatment of Chronic Anal Fissure: a Randomised Controlled Trial Phase 4
Completed NCT04173130 - Monocentric Feasibility Study for a New Medical Device for the Treatment of Anal Fissure With Botulinum Toxin N/A
Completed NCT03345511 - Ultrasound Guided Caudal Block for Benign Anal Surgery N/A
Completed NCT05341180 - Efficacy of Polyethylene Glycol vs Lactulose With Isabgol in Acute Fissure-in-Ano: PEGASIS Trial Phase 2/Phase 3
Completed NCT03528772 - Topical Minoxidil Versus Topical Glyceryl Trinitrate in Treatment of Chronic Anal Fissure N/A
Active, not recruiting NCT04428697 - Sungurtekin Technique vs. Closed Lateral Internal Sphincterotomy Technique N/A
Withdrawn NCT01920074 - Pharmacokinetic,Safety and Exploratory Efficacy of RECTIV® in Adolescents With Chronic Anal Fissure Phase 4
Recruiting NCT01039051 - Diet and Lifestyle Intervention Study in Postpartum Women in China Phase 2/Phase 3
Completed NCT00210444 - Efficacy Study of Dysport® in the Treatment of Anal Fissure. Phase 2
Completed NCT00827736 - Comparison of Treatment Success of Botox Injection in the Internal Sphincter Versus Isosorbidedinitrate Ointment in Patients With an Anal Fissure Phase 4
Withdrawn NCT02667535 - PK, PD and Safety Comparative Trial of Isosorbide Mononitrate Gel in Healthy Participants and With Anal Fissure Phase 1
Not yet recruiting NCT06049524 - Could Preoperative Assessment of Physical and Psychological Status Help Predict Pain After Anorectal Surgery?
Not yet recruiting NCT05709717 - Regenerative Therapy With Autologous Stromal Vascular Fraction Derived Mesenchymal Stem Cells and Platelet-rich Plasma to Treat Complex Perianal Diseases
Completed NCT05038605 - Topical vs Oral Metronidazole After Benign Anorectal Surgery N/A
Not yet recruiting NCT03780998 - Effects of Sodium Pentaborat Based Gel on Perianal Benign Diseases
Completed NCT03426449 - Posterolateral Versus Lateral Internal Anal Sphincterotomy for Chronic Anal Fissure N/A